Prurigo Nodularis Market Research
What is Prurigo Nodularis?
Prurigo Nodularis (PN) is a chronic skin condition that causes hard, itchy nodules to develop on the skin. These nodules can range in size from a few millimeters to several centimeters and can occur anywhere on the body. They are usually found in clusters and can be very uncomfortable and distressing for those who have them.
While the exact cause of PN is not fully understood, it is believed to be related to a problem with the immune system or the nerves that transmit sensations from the skin to the brain. It is more common in people with other skin conditions such as eczema or psoriasis, and it can also be triggered by insect bites or other irritants. There is no cure for PN, but treatments such as topical creams, oral medications, and light therapy can help to manage the symptoms and reduce the severity of the nodules.
Spherix Global Insights – Dermatology – Prurigo Nodularis
Spherix Global Insights’ Dermatology therapeutic team is a leading provider of independent syndicated Prurigo Nodularis market research, insights, business intelligence & advisory services.
Spherix’s Dermatology team covers studies publishing this year in their Market Dynamix™ and Launch Dynamix™ services including:
- Market Dynamix™: Prurigo Nodularis (US)
- Launch Dynamix™: Dupixent (Sanofi/Regeneron) in Prurigo Nodularis (US)
- Launch Dynamix™: Nemolizumab (Galderma) in Prurigo Nodularis (US)*
*Pending drug approval
Spherix’s Market Dynamix™ service is based on dermatologists and key opinion leader feedback in the form of surveys and qualitative interviews. The reports consist of an analysis of markets anticipated to experience a paradigm shift within 3-5 years. Insights highlight market size, current treatment approaches, unmet needs, and expert opinions on the likely disruption introduced by pipeline agents.
Spherix’s Launch Dynamix™ service consists of two parts: monthly KPI tracking and quarterly deep dives. Monthly KPIs provide monthly benchmarking of newly launched products which includes for the first eighteen months of commercial availability, and quarterly deep dive reports includes promotional activity, barriers to uptake, and patient types gravitating to the launch brand.
Follow Spherix Dermatology on Social Media
Follow us for dermatology industry news, insights & analysis:
For Guests & Current Clients
For more details on Spherix’s primary market research reports and interactive dashboard offerings, visit or register here: https://clientportal.spherixglobalinsights.com